SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-002474
Filing Date
2023-02-10
Accepted
2023-02-10 16:16:33
Documents
12
Period of Report
2023-02-07
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K dice-20230207.htm   iXBRL 8-K 49837
  Complete submission text file 0000950170-23-002474.txt   170710

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dice-20230207_pre.xml EX-101.PRE 10303
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dice-20230207_lab.xml EX-101.LAB 14018
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dice-20230207.xsd EX-101.SCH 2493
6 EXTRACTED XBRL INSTANCE DOCUMENT dice-20230207_htm.xml XML 4942
Mailing Address 279 E. GRAND AVENUE, SUITE 300, LOBBY B SOUTH SAN FRANCISCO CA 94080
Business Address 279 E. GRAND AVENUE, SUITE 300, LOBBY B SOUTH SAN FRANCISCO CA 94080 650-566-1402
DICE Therapeutics, Inc. (Filer) CIK: 0001645569 (see all company filings)

IRS No.: 472286244 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40794 | Film No.: 23612115
SIC: 2834 Pharmaceutical Preparations